Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibα-immunoglobulin G1 chimeric proteins

Pharmaceutical Research

Volumn 23, Issue 8, 2006, Pages 1743-1749

  Wang, Qin ^a   Shorten, Douglas ^a   Xu, Xin ^a   Shaw, Gray D ^a   Schaub, Robert G ^a   Shea, Christopher ^a   Brooks, Jonathan ^a   Sako, Dianne ^a   Wiswall, Erin ^a   Xu, Jin ^a   Szklut, Pamela ^a   Patel, Vikram S ^a  

^a PFIZER INC   (United States)

Author keywords

Factor VIII; GPIb _Ig; Pharmacokinetics of recombinant protein; vWF; vWF antibody

Indexed keywords

CHIMERIC PROTEIN; RECOMBINANT HUMAN PLATELET GLYCOPROTEIN IBALPHA IMMUNOGLOBULIN G1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VALINE; VON WILLEBRAND FACTOR;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CONCENTRATION RESPONSE; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; EXPERIMENTAL ANIMAL; FEMALE; MALE; MOUSE; NONHUMAN; PRECIPITATION; PRIORITY JOURNAL; RAT; THROMBOCYTE ADHESION; TIME;

AMINO ACID SUBSTITUTION; ANIMALS; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; MALE; MICE; MICE, KNOCKOUT; MUTANT CHIMERIC PROTEINS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; VALINE; VON WILLEBRAND FACTOR;

EID: 33746864554     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9018-1     Document Type: Article

References (32)

1. Z. M. Ruggeri. von Willebrand factor. Curr. Opin. Hematol. 10:142-149 (2003).
2. A. Bonnefoy, J. Vermylen, and M. F. Hoylaerts. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev. Cardiovasc. Ther. 1:257-269 (2003).
3. F. Li, C-Q. Li, J. L. Moake, J. A. Lopez, and L. V. McIntire. Shear stress-induced binding of large and unusually large von Willebrand Factor To Human Platelet Glycoprotein Ibα. Ann. Biomed. Eng. 32:961-969 (2004).
4. W. F. Richter, H. Gallati, and C. D. Schiller. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to human. Drug. Metab. Dispos. 27:21-25 (1999).
5. G. N. Cox, D. J. Smith, S. J. Carlson, A. M. Bendele, E. A. Chlipala, and D. H. Doherty. Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Exp. Hematol. 32:441-449 (2004).
6. S-P. Khor, K. McCarthy, M. DuPont, K. Murray, and G. Timony. Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. J. Pharmacol. Exp. Ther. 293:618-624 (2000).
7. R. A. Kumar, J. F. Dong, J. A. Thaggard, M. A. Cruz, J. A. Lopez, and L. V. McIntire. Kinetics of GPIbα-vWF-A1 tether bond under flow: effect of GPIbα mutations on the association and dissociation rates. Biophys. J. 85:4099-4109 (2003).
8. L. Dong, A. J. Schade, G. M. Romo, R. K. Andrews, S. Gao, L. V. McIntire, and J. A. Lopez. Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J. Biol. Chem. 275:27663-27670 (2000).
9. C. Denis, N. Methia, P. S. Frenette, H. Rayburn, M. Ullman-Cullere, R. O. Hunes, and D. Wanger. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USA. 95:9524-9529 (1998).
10. L. C. Miller, D. Cunningham, V. A. Lyle, and C. N. Finch. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc. Natl. Acad. Sci. USA 88:4761-4765 (1991).
11. H. Takahashi, M. Murata, T. Moriki, H. Anbo, T. Furukawa, K. Nikkuni, A. Shibata, M. Handa, Y. Kawai, and K. Watanabe. Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood 85:727-733 (1995).
12. J. E. Sadler. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67:395-424 (1998).
13. M. I. Bazin-Redureau, C. B. Renard, and J. M. Scherrmann. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat. J. Pharm. Pharmacol. 49:277-281 (1997).
14. 2-fragments and β-propiolactone treated IgG) in dogs. Res. Exp. Med. 173:209-218 (1978).
15. R. E. Benson, J. L. Catalfamo, and W. J. Dodds. A multispecies enzyme-linked immunosorbent assay for von Willebrand's factor. J. Lab. Clin. Med. 119:420-427 (1992).
16. M. S. Read, J. Y. Potter, and K. M. Brinkhous. Venom coagglutinin for detection of von Willebrand factor activity in animal plasmas. J. Lab. Clin. Med. 101:74-82 (1983).
17. S. Kageyama, H. Yamamoto, H. Nakazawa, J. Matsushita, T. Kouyama, A. Gonsho, Y. Ikeda, and R. Yoshimoto. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler. Thromb. Vasc. Biol. 22:187-192 (2002).
18. L. J. Benincosa, F. S. Chow, L. P. Tobia, D. C. Kwok, C. B. Davis, and W. J. Jusko. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 292:810-816 (2000).
19. T. K. Hart, R. M. Cook, P. Zia-Amirhosseini, E. Minthorn, T. S. Sellers, B. E. Maleeff, S. Eustis, L. W. Schwartz, P. Tsui, E. R. Appelbaum, E. C. Martin, P. J. Bugelski, and D. J. Herzyk. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J. Allergy. Clin. Immunol. 108:250-257 (2001).
20. N. M. Ananyeva, D. V. Kouiavskaia, M. Shima, and E. L. Saenko. Catabolism of the coagulation factor VIII: can we prolong lifetime of f VIII in circulation? Trends Cardiovasc. Med. 11:251-257 (2001).
21. E. L. Saenko, A. V. Yakhyaev, I. Mikhailenko, D. K. Strickland, and A. G. Sarafanov. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J. Biol. Chem. 274:37685-37692 (1999).
22. P. J. Lenting, E. Westein, V. Terraube, A. S. Ribba, E. G. Huizinga, D. Meyer, P. G. Groot, and C. V. Denis. An experimental model to study the in vivo survival of von Willebrand factor. J. Biol. Chem. 279:12102-12109 (2004).
23. J. H. Stoddart Jr., J. Andersen, and D. C. Lynch. Clearance of normal and type 2A von Willebrand factor in the rat. Blood 88:1692-1699 (1996).
24. J. Mordentia, G. Osakaa, K. Garciab, K. Thomsena, V. Lickoa, and G. Meng. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol. Appl. Pharmacol. 136:75-78 (1996).
25. T. Stokol, L. Trepanier, B. W. Parry, and B. C. Finnin. Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A. Res. Vet. Sci. 63:23-27 (1997).
26. P. L. Turecek, H. Gritsch, L. Pichler, W. Auer, B. Fischer, A. Mitterer, W. Mundt, U. Schlokat, F. Dorner, H. J. M. Brinkman, J. A. Mourik, and H. P. Schwarz. In Vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 90:3555-3567 (1997).
27. K. Brinkhous, H. Sandberg, L. Widlund, M. Read, T. Nichols, J. Sigman, U. Oswaldsson, R. G. Schaub, and M. Mikaelsson. Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII. Semin. Thromb. Hemostasis 28:269-272 (2002).
28. H. P. Schwarz, F. Dorner, A. Mitterer, W. Mundt, U. Schlokat, L. Pichler, and P. L. Turecek. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease. Haemophilia 4(Suppl 3):53-62 (1998).
29. M. Morfini. Pharmacokinetics of factor VIII and factor IX. Haemophilia 9(Suppl 1):94-100 (2003).
30. A. J. Vlot, E. P. Mauser-Bunschoten, A. G. Zarkova, E. Haan, C. L. Kruitwagen, J. J. Sixma, and H. M. Berg. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb. Haemostasis. 83:65-69 (2000).
31. J. O'Donnell and M. A. Laffan. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transf. Med. 11:343-351 (2001).
32. C. H. Miller, E. Haff, S. J. Platt, P. Rawlins, C. D. Drews, A. B. Dilly, and B. Evatt. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J. Thromb. Heamostasis 1:2191-2197 (2002).